Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat - Biologic Drug Details

Summary for allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-DSAT

Last updated: February 27, 2026

What is the current landscape for allogeneic cultured keratinocytes and dermal fibroblasts?

Allogeneic cultured keratinocytes and dermal fibroblasts are cell-based biologic therapies under development for skin regeneration and wound healing. These products are primarily aimed at burn treatment, chronic wounds, and cosmetic applications. The products leverage advances in tissue engineering, utilizing murine collagen as a scaffold—specifically in dermal substitute active therapy (DSAT).

The biologic’s focus is to improve healing times, reduce scarring, and minimize the need for autografting. Key players include startups and biotech firms advancing cell cultivation and scaffold integration, with some progressing through clinical trials.

How do market drivers impact development and adoption?

• Clinical unmet needs: Chronic wounds affect approximately 6.5 million patients in the U.S. alone, with wound care market valued at $20 billion in 2022. The demand for effective regenerative therapies fuels development.
• Regulatory landscape: Approval pathways for cell-based therapies remain complex. The FDA has approved several skin substitutes under the Humanitarian Device Exemption (HDE) or Premarket Approval (PMA).
• Technological advancements: Innovations in culture techniques, scaffold design, and cytokine support expand product efficacy and safety profiles.
• Reimbursement policies: Coverage for advanced wound care products varies by region, influencing commercial viability.

How does the product's pipeline status influence market potential?

Development Stage	Number of Programs	Notable Examples	Timeline Expectations
Preclinical	8-12	Various startups focusing on murine collagen scaffolds	1-3 years for IND filing
Clinical Trials	4-6	Phase 1/2 trials for burn and diabetic ulcers	3-5 years to market approval
Regulatory Approval	2-3	Early-stage applications in USA and EU	2-4 years post-trial completion

The pipeline is concentrated in early and mid-stage development, indicating potential for expansion but requiring substantial R&D investment.

What is the financial outlook for this biologic in the coming years?

Market analysts project the global regenerative skin market will grow at 12% CAGR from 2022 to 2030. The biologic segment, including cell-based therapies, is expected to capture a significant share, reaching an estimated valuation of $5 billion by 2030.

Price points vary by product and indication, generally ranging from $10,000 to $50,000 per treatment. High treatment costs, coupled with limited reimbursement in early adoption phases, could restrict initial market penetration.

Key factors influencing revenue include:

• Product efficacy and safety profiles
• Regulatory milestones
• Strategic collaborations for distribution
• Reimbursement policy adjustments

How do competitive dynamics shape the market?

Major competitors include advanced wound care companies such as Organogenesis, Acelity, and Integra LifeSciences. These companies produce both cell-based and scaffold-based products, influencing market share and pricing strategies.

Emerging biotech firms focus on refining scaffold composition, reducing manufacturing costs, and enhancing cell viability. Innovation in allogeneic approaches allows for off-the-shelf availability, reducing logistics and patient preparation costs.

Market entry strategies often involve partnerships with hospitals, wound care centers, and insurance providers to facilitate adoption.

What are key regulatory and reimbursement considerations?

Regulatory pathways differ between regions:

• FDA: Requires extensive safety and efficacy data, with pathways such as HDE for rare conditions.
• EMA: Similar requirements, with additional emphasis on manufacturing quality controls.

Reimbursement remains inconsistent, with payers requiring evidence of clinical benefit and cost-effectiveness. Early engagement with payers and health authorities is critical for favorable coverage decisions.

Summarized financial trajectory

Year	Market Size ($ billion)	CAGR	Key Opportunities	Challenges
2022	N/A (Pre-commercial)	N/A	R&D funding, clinical trial completion	Regulatory hurdles, high R&D costs
2025	0.5	15-20%	Product approvals, early adopters	Reimbursement uncertainty
2030	5	12%	Market expansion, pricing strategies	Competition, manufacturing scalability

Final assessment

The biologic therapy involving allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen scaffolds holds potential for significant market growth. Execution remains contingent on successful clinical outcomes, regulatory approval, and reimbursement policies.

Key Takeaways

• The cell-based biologic is in early development, with clinical trials underway.
• The regenerative skin market is expanding, driven by unmet clinical needs.
• Regulatory pathways are emerging, with approval timelines extending over several years.
• Financial projections anticipate substantial growth, contingent on market access and product efficacy.
• Competition from established wound care firms and biotech startups will influence pricing and adoption rates.

FAQs

1. What are the main advantages of allogeneic compared to autologous cell therapies?
Allogeneic therapies are off-the-shelf, reducing preparation time and costs associated with autologous cell harvesting.

2. How does murine collagen scaffolding influence regulatory approval?
Murine collagen introduces potential zoonotic transmission concerns, requiring stringent safety testing and quality controls.

3. What clinical indications are most promising for this biologic?
Chronic wounds, including diabetic foot ulcers and burns, present the largest unmet needs for allogeneic cell therapies.

4. How is the market responding to new biologic skin substitutes?
Response varies; early products face slow adoption due to regulatory and reimbursement hurdles but show promise in improving healing times.

5. What are potential barriers to commercialization?
Manufacturing complexity, high R&D costs, regulatory approval delays, and reimbursement challenges can slow market entry.

---

References

1. American Burn Association. (2022). Burn incidence and epidemiology.
2. MarketWatch. (2022). Regenerative Skin Market Size, Share & Trends.
3. U.S. Food and Drug Administration. (2021). Guidance documents for cell-based therapies.
4. Grand View Research. (2023). Wound Care Market Size and Forecast.
5. European Medicines Agency. (2021). Regulatory pathway for advanced therapy medicinal products.